NFE2L2 and breast carcinoma: Taken together, these data indicate that, in most cases, NRF2 mediates a therapy resistance in breast cancer cells in response to the altered redox balance caused by anticancer drug administration, but this does not exclude the possibility that other types of mechanisms, ROS-independent, might also account for enhanced NRF2 signaling under different biological contexts.